FDA allows wider use of Spectrum's cancer drug Fusilev

05/1/2011 | Forbes

The FDA approved Spectrum Pharmaceuticals' injectable drug Fusilev for use with 5-fluorouracil to treat metastatic colorectal cancer. Fusilev was first approved in 2008 for reducing toxicity of methotrexate, a chemotherapy drug, in patients with a rare form of bone cancer, osteosarcoma.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN